Angiogenic factors in multiple myeloma: Higher levels in bone marrow than in peripheral blood

Haematologica

Volumn 85, Issue 8, 2000, Pages 800-805

  Di Raimondo, F ^a   Azzaro, M P ^a   Palumbo, G A ^a   Bagnato, S ^a   Giustolisi, G ^a   Floridia, P M ^a   Sortino, G ^a   Giustolisi, R ^a  

^a Ospedale Ferrarotto   (Italy)

Author keywords

Angiogenesis; Bone marrow; Myeloma

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; ERYTHROPOIETIN; M PROTEIN; SCATTER FACTOR; VASCULOTROPIN;

ADULT; AGE; AGED; ANGIOGENESIS; ARTICLE; BONE ATROPHY; BONE MARROW; CANCER STAGING; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPOXIA; MULTIPLE MYELOMA; PLASMA CELL; PROTEIN BLOOD LEVEL;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BONE MARROW; CELL COUNT; COMPARATIVE STUDY; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEPATOCYTE GROWTH FACTOR; HUMAN; INTERFERON-ALPHA; LYMPHOKINES; MALE; MIDDLE AGE; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PLASMA CELLS; PLASMACYTOMA; SUPPORT, NON-U.S. GOV'T; TUMOR STEM CELLS;

EID: 0033835945     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bone marrow angiogenesis and progression in multiple myeloma
2. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
3. Antitumor activity of thalidomide in refractory multiple myeloma
4. Vascular development: Cellular and molecular regulation
5. Biology of vascular endothelial growth factor
6. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease
7. Growth factors in POEMS syndrome: Evidence for a marked increase in circulating vascular endothelial growth factor
8. VEGF is expressed by myeloma cells and stimulates IL-6 secretion by microvascular endothelial and marrow stromal cells
9. Interleukln 6 induces the expression of vascular endothelial growth factor
10. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
11. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancer
12. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine
13. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma
14. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia
15. Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: A multifunctional regulator of cell behavior within the tumor microenvironment
16. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth
17. Hepatocyte growth factor is involved in formation of osteoclast-like cells mediated by clonal stromal cells (MC3T3-G2/PA6)
18. The effect of hepatocyte growth factor on the behavior of osteoclasts
19. Concomitant expression of hepatocyte growth factor/scatter factor and its receptor c-Met in human myeloma cell lines
20. Hepatocyte growth factor and its receptor c-Met in multiple myeloma
21. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma
22. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology
23. Mechanism of the synergistic effect of heparin and cortisone against angiogenesis and tumor growth
24. Synergistic effect of retinoids and interferon α on tumor-induced angiogenesis: Anti-angiogenic effect on HPV-harboring tumor-cell lines
25. Tumor vascularity as a prognostic factor in cancer
26. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption
27. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: A possible role for HGF in myeloma-associated bone disease
28. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells
29. The role of hepatocyte growth factor and its receptor c-met in multiple myeloma and other blood malignancies
30. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor
31. Treatment of multiple myeloma
32. Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma
33. Therapeutic potentials of angiostatin in the treatment of cancer